Three Canadian researchers and two pharmaceutical companies honoured for outstanding innovations in Canadian healthcare

Three Canadian researchers and two pharmaceutical companies honoured for 
outstanding innovations in Canadian healthcare 
TORONTO, Nov. 14, 2012 /CNW/ - The Health Research Foundation has awarded its 
prestigious Medal of Honour to Dr. Charles Scriver and Mr. Arnold Steinberg 
for their outstanding contributions to health sciences and public health 
innovation during a ceremony held in Toronto today. The ceremony was co-hosted 
with Prix Galien Canada. 
"The Health Research Foundation is proud to award the Medal of Honour to Dr. 
Charles Scriver and Mr. Arnold Steinberg," said Ms. Teresa Bitetti, Interim 
Chair, Rx&D Health Research Foundation and General Manager, Bristol-Myers 
Squibb Canada. "Above and beyond their extraordinary impact on the health of 
young Canadians, they have both exemplified a life of dedication to academic 
Together, Dr. Scriver and Mr Steinberg successfully worked to ensure the 
addition of vitamin D to milk in Quebec starting in the early 1970s, reducing 
the occurrence of nutritional rickets in children from over 1,000 per year to 
almost none. They have also collaborated on the development of the National 
Food Distribution Centre for the Management of Patients with Hereditary 
Metabolic Disease. The Centre focusses on the development of special diets as 
treatment for children with genetic disorders, including importing, storage 
and distribution of specialized dietary products. Dr. Scriver is a Professor 
at McGill University and a world-renowned geneticist and pioneer in the study 
of genetic diseases of children, especially resulting from inborn errors of 
metabolism. Mr Steinberg is the current Chancellor of McGill University, a 
philanthropist and has provided leadership to the Canadian Institutes of 
Health Research, the Canadian Patient Safety Initiative, Health Infoway, and 
the McGill University Health Centre, to name a few. 
The Health Research Foundation co-hosted the award ceremony with Prix Galien, 
who awarded the Prix Galien Canada 2012 Research to Dr. Robert E.W. Hancock, 
Professor of Microbiology and Immunology at the University of British Columbia 
and Canada Research Chair holder. Dr. Hancock has made major contributions to 
the area of microbiology and antimicrobial agents and has shown scientific 
leadership on many fronts. He has been involved in the founding of many 
scientific and biotechnology organizations and companies. His breakthrough 
discovery of a novel way of selectively modulating immunity and suppressing 
harmful inflammation while retaining protective immunity has, according to 
Prix Galien Canada, the potential to revolutionize human healthcare. 
The Prix Galien Canada 2012-Innovative product was awarded to Incivek 
(telaprevir) marketed by Vertex Pharmaceuticals Canada Ltd and to Victrelis 
(boceprivir) marketed by Merck Canada Inc. Incivek and Victrelis are the first 
two direct acting antivirals available in Canada for the treatment of chronic 
genotype 1 hepatitis C infection. The protease inhibitors have been shown to 
be very effective and appear to have shortened the duration of the treatment 
for chronic genotype 1 hepatitis C infection. They represent a significant 
improvement in the treatment of the disease and should be considered a real 
About the Rx&D Health Research Foundation (HRF)
The Rx&D Health Research Foundation is a non-profit organization whose mission 
is to support health research in Canadian academic health centres and promote 
the value of health research in Canada. By applying the highest standards of 
scientific excellence, addressing health challenges and establishing 
partnerships, HRF, one of the leading private health foundations in the 
country, contributes significantly to the prevention and treatment of disease, 
to a better health care system and the availability for Canadians to access 
effective health products. 
About Canada's Research-Based Pharmaceutical Companies (Rx&D)
Rx&D is the association of leading research-based pharmaceutical companies 
dedicated to improving the health of Canadians through the discovery and 
development of new medicines and vaccines. Our community represents the men 
and women working for more than 50 member companies which invest more than $1 
billion in research and development each year to fuel Canada's knowledge-based 
economy, contributing over $3 billion to the Canadian economy. Guided by our 
Code of Ethical Practices, our membership is committed to working in 
partnership with governments, healthcare professionals and stakeholders in a 
highly ethical manner. 
About The Prix Galien
The Prix Galien is the most prestigious award in the field of Canadian 
pharmaceutical research and innovation. Referred to as the Nobel Prize of 
pharmaceutical research, it recognizes the efforts and achievements of 
pharmaceutical research and development. The Prix Galien Canada is a branch of 
Innovation Life Canada. The mission of Innovation Life Canada is to celebrate 
innovators in life sciences through the organization of events for the general 
public and most importantly the younger generations. These events will bring 
an educational twist by gathering together the winners of our various awards 
and distinctions and affording them the opportunity to share their knowledge 
and experiences with the next generation. Innovation Life Canada is a 
non-profit organization. 
For more information on the HRF Medal of Honour: 
Isabelle Robillard Media Relations Telephone: 613-236-0455 (extension 831) 
For more information on the Prix Galien: 
Telephone: 514-216-2513 
To view this news release in HTML formatting, please use the following URL: 
ST: Ontario
-0- Nov/15/2012 01:45 GMT
Press spacebar to pause and continue. Press esc to stop.